Advanced or metastatic gastric or GEJ adenocarcinoma
Clinical trial design: REGARD
REGARD: The pivotal phase III trial for CYRAMZA monotherapy (N=355)1
A multicenter, randomized, placebo-controlled, double-blind trial of patients with locally advanced or metastatic gastric or GEJ adenocarcinoma previously treated with fluoropyrimidine- or platinum-containing chemotherapy*
REGARD TRIAL DESIGN1
- Major Efficacy Outcome Measure: Overall survival.
- Supportive Efficacy Outcome Measure: Progression-free survival.
- The REGARD trial did not include or exclude patients based on any specific biomarker2